LIVIVO - Search results -

Search results

Result 1 - 10 of total 36

Search options

Article ; Online: Influence of conversion factors on the radioactivity evaluation of clearance objects consisting of several materials.

Yoshii, Taiki / Sakai, Hirotaka / Kawarabayashi, Jun

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine

2023 Volume 200, Page(s) 110984

Abstract: Control panel waste generated from nuclear power plants is a new candidate for clearance under Japan's amended regulations. In the radioactivity evaluation, a simplified conversion factor for density and source location conditions has been used, assuming ...

Abstract	Control panel waste generated from nuclear power plants is a new candidate for clearance under Japan's amended regulations. In the radioactivity evaluation, a simplified conversion factor for density and source location conditions has been used, assuming that it applies to unmixed materials such as metals. To investigate its applicability to control panels consisting of metal and organic materials, we examined the application of the conventional conversion factor by simulations of radiation measurements for a point source in a control panel.
Language	English
Publishing date	2023-08-15
Publishing country	England
Document type	Journal Article
ZDB-ID	1142596-9
ISSN	1872-9800 ; 0883-2889 ; 0969-8043
ISSN (online)	1872-9800
ISSN	0883-2889 ; 0969-8043
DOI	10.1016/j.apradiso.2023.110984
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ue I Zs.279: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The effect of introducing a nurse-practitioner-led peripherally inserted central venous catheter placement program on the utilization of central venous access device: A retrospective study in Japan.

Sakai, Hirotaka / Hirosue, Miyuki / Iwata, Mitsunaga / Terasawa, Teruhiko

The journal of vascular access

2023 , Page(s) 11297298231173160

Abstract: Background: Nurse-led peripherally inserted central venous catheter (PICC) placement teams are common in western hospitals, but they are still in their infancy in Japan. Although implementing a dedicated program may improve ongoing vascular-access ... ...

Abstract	Background: Nurse-led peripherally inserted central venous catheter (PICC) placement teams are common in western hospitals, but they are still in their infancy in Japan. Although implementing a dedicated program may improve ongoing vascular-access management, the direct hospital-level effects of launching a nurse-led PICC team on specific outcomes have not been formally investigated. Objectives: To evaluate the effect of introducing a nurse practitioner (NP)-led PICC-placement program on subsequent utilization of centrally inserted central catheters (CICCs) and to contrast the quality of PICC placements conducted by physicians and NPs. Materials and methods: Patients who underwent central venous access devices (CVADs) between 2014 and 2020 at a university hospital in Japan were evaluated retrospectively using an interrupted time-series analysis on the trend for monthly CVAD utilization and logistic regression and propensity score-based analyses for PICC-related complications. Results: Among 6007 CVAD placements, 2230 PICCs were inserted into 1658 patients (725 by physicians and 1505 by NPs). The monthly number of CICC utilization fell from 58 in April 2014 to 38 in March 2020, while PICC placements by the NP PICC team increased from 0 to 104. The implementation of the NP PICC program reduced the immediate rate (by 35.5; 95% confidence interval [CI]: 24.1-46.9; Conclusions: This NP-led PICC program reduced CICC utilization without affecting the quality of PICC placement or complication rate.
Language	English
Publishing date	2023-06-21
Publishing country	United States
Document type	Journal Article
ZDB-ID	2252820-9
ISSN	1724-6032 ; 1129-7298
ISSN (online)	1724-6032
ISSN	1129-7298
DOI	10.1177/11297298231173160
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6414: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Quantitative evaluation of treatment response to lenalidomide by applying fluorescence in situ hybridization for peripheral blood granulocytes in a patient with 5q- syndrome.

Sakai, Hirotaka / Miura, Ikuo / Arai, Ayako

Journal of clinical and experimental hematopathology : JCEH

2022 Volume 62, Issue 3, Page(s) 158–163

Abstract: The introduction of lenalidomide has significantly improved clinical outcomes in myelodysplastic syndrome (MDS) with isolated interstitial deletion of the long arm of chromosome 5 (del(5q)) (5q- syndrome). These days, MDS with isolated del(5q) includes ... ...

Abstract	The introduction of lenalidomide has significantly improved clinical outcomes in myelodysplastic syndrome (MDS) with isolated interstitial deletion of the long arm of chromosome 5 (del(5q)) (5q- syndrome). These days, MDS with isolated del(5q) includes cases with one additional chromosome abnormality other than monosomy 7 or del(7q), and so we need a better way to monitor tumor cells in each patient than the clinical parameters used to date. An 82-year-old woman with MDS with isolated del(5q) was treated with lenalidomide daily for 21 days in a 4-week cycle. Fluorescence in situ hybridization with CSF1R located at 5q was applied to the peripheral blood samples. Because mature lymphocytes are not involved in the MDS clone, based on the nuclear morphology, polymorphonuclear cells (PMNs) and round-shaped nuclear cells (RSNs) were separately evaluated during treatment. After a single course of treatment, the number of PMNs with del(5q) decreased; by the end of the second course of treatment, both PMNs and RSNs with del(5q) had disappeared. The dynamics of 5q- PMNs is a simple but rapid and reliable indicator to confirm the effect of lenalidomide in MDS with del(5q).
MeSH term(s)	Aged, 80 and over ; Anemia, Macrocytic ; Chromosome Deletion ; Chromosomes, Human, Pair 5/genetics ; Cri-du-Chat Syndrome ; Female ; Granulocytes/pathology ; Humans ; In Situ Hybridization, Fluorescence ; Lenalidomide/therapeutic use ; Myelodysplastic Syndromes/drug therapy ; Myelodysplastic Syndromes/genetics ; Myelodysplastic Syndromes/pathology ; Thalidomide/therapeutic use ; Trisomy
Chemical Substances	Thalidomide (4Z8R6ORS6L) ; Lenalidomide (F0P408N6V4)
Language	English
Publishing date	2022-06-22
Publishing country	Japan
Document type	Case Reports ; Journal Article
ZDB-ID	2395568-5
ISSN	1880-9952 ; 1880-9952
ISSN (online)	1880-9952
ISSN	1880-9952
DOI	10.3960/jslrt.22001
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Successful Treatment of an Aggressive Adult T-cell Leukemia/Lymphoma with Strong CD30 Expression Using Brentuximab Vedotin as Combination and Maintenance Therapy.

Baba, Yuta / Sakai, Hirotaka / Kabasawa, Nobuyuki / Harada, Hiroshi

Internal medicine (Tokyo, Japan)

2022 Volume 62, Issue 4, Page(s) 613–616

Abstract: Adult T-cell leukemia/lymphoma (ATL) is a highly aggressive malignant tumor associated with a poor prognosis. We herein report a 63-year-old man who was newly diagnosed with aggressive ATL. He was treated with brentuximab vedotin (BV) plus ... ...

Abstract	Adult T-cell leukemia/lymphoma (ATL) is a highly aggressive malignant tumor associated with a poor prognosis. We herein report a 63-year-old man who was newly diagnosed with aggressive ATL. He was treated with brentuximab vedotin (BV) plus cyclophosphamide, doxorubicin, and prednisone (A+CHP therapy), along with intrathecal chemotherapy using methotrexate and cytarabine. After achieving remission, he was placed on maintenance therapy with BV in the outpatient setting every 21 days for 17 months, without relapse. We suggest that initial treatment with A+CHP therapy and BV maintenance therapy may be beneficial against strongly CD30-expressing ATL.
MeSH term(s)	Adult ; Male ; Humans ; Middle Aged ; Brentuximab Vedotin/therapeutic use ; Immunoconjugates/therapeutic use ; Leukemia-Lymphoma, Adult T-Cell/drug therapy ; Cyclophosphamide/therapeutic use ; Lymphoma/drug therapy
Chemical Substances	Brentuximab Vedotin (7XL5ISS668) ; Immunoconjugates ; Cyclophosphamide (8N3DW7272P)
Language	English
Publishing date	2022-07-22
Publishing country	Japan
Document type	Case Reports ; Journal Article
ZDB-ID	32371-8
ISSN	1349-7235 ; 0021-5120 ; 0918-2918
ISSN (online)	1349-7235
ISSN	0021-5120 ; 0918-2918
DOI	10.2169/internalmedicine.9812-22
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 240: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Successful Treatment of Immune Thrombocytopenic Purpura with Intracranial Hemorrhaging and Duodenal Bleeding Following SARS-CoV-2 Vaccination.

Baba, Yuta / Sakai, Hirotaka / Kabasawa, Nobuyuki / Harada, Hiroshi

Internal medicine (Tokyo, Japan)

2022 Volume 61, Issue 12, Page(s) 1891–1895

Abstract: Several vaccines have been developed for coronavirus disease 2019 - caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - in record time. A few cases of immune thrombocytopenic purpura (ITP) following SARS-CoV-2 vaccination have ... ...

Abstract	Several vaccines have been developed for coronavirus disease 2019 - caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - in record time. A few cases of immune thrombocytopenic purpura (ITP) following SARS-CoV-2 vaccination have been reported. We herein report a 90-year-old man who received the Pfizer-BioNTech SARS-CoV-2 vaccine (BNT162b2) and developed severe thrombocytopenia with intracranial hemorrhaging and duodenal bleeding, consistent with vaccine-related ITP. He was successfully treated with intravenous immunoglobulin, prednisolone, and eltrombopag and discharged without cytopenia. Vaccine-related ITP should be suspected in patients presenting with abnormal bleeding or purpura after vaccination.
MeSH term(s)	Aged, 80 and over ; BNT162 Vaccine/adverse effects ; COVID-19 ; Humans ; Intracranial Hemorrhages/chemically induced ; Intracranial Hemorrhages/drug therapy ; Male ; Purpura, Thrombocytopenic, Idiopathic/chemically induced ; Purpura, Thrombocytopenic, Idiopathic/drug therapy ; Thrombocytopenia/chemically induced ; Thrombocytopenia/drug therapy ; Vaccination/adverse effects
Chemical Substances	BNT162 Vaccine (N38TVC63NU)
Language	English
Publishing date	2022-04-09
Publishing country	Japan
Document type	Case Reports ; Journal Article
ZDB-ID	32371-8
ISSN	1349-7235 ; 0021-5120 ; 0918-2918
ISSN (online)	1349-7235
ISSN	0021-5120 ; 0918-2918
DOI	10.2169/internalmedicine.9199-21
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 240: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Extranodal NK/T-cell lymphoma in a unilateral adrenal tumor.

Baba, Yuta / Sakai, Hirotaka / Abe, Maasa / Kabasawa, Nobuyuki

Japanese journal of clinical oncology

2022 Volume 52, Issue 12, Page(s) 1450–1451

MeSH term(s)	Humans ; Lymphoma, Extranodal NK-T-Cell/diagnostic imaging ; Lymphoma, Extranodal NK-T-Cell/pathology ; Adrenal Gland Neoplasms/diagnostic imaging ; Adrenal Gland Neoplasms/surgery
Language	English
Publishing date	2022-08-22
Publishing country	England
Document type	Journal Article
ZDB-ID	190978-2
ISSN	1465-3621 ; 0368-2811
ISSN (online)	1465-3621
ISSN	0368-2811
DOI	10.1093/jjco/hyac134
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1298: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Evaluation of the probability distribution of radioactivity estimated by inverse problem solution using Monte Carlo Method.

Sakai, Hirotaka / Yoshii, Taiki / Yunoki, Akira

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine

2022 Volume 187, Page(s) 110338

Abstract: In this study, we derived the posterior probability distribution of the total activity estimated by inverse problem solution. The posterior probability distribution was derived by applying the Monte Carlo approach of the GUM Supplement 1 to the model of ... ...

Abstract	In this study, we derived the posterior probability distribution of the total activity estimated by inverse problem solution. The posterior probability distribution was derived by applying the Monte Carlo approach of the GUM Supplement 1 to the model of evaluation. The decision threshold, the detection limit, and the limits of the coverage interval for the results, all of which are defined in ISO 11929-2 as characteristic limits, were also derived.
MeSH term(s)	Monte Carlo Method ; Probability ; Radioactivity
Language	English
Publishing date	2022-06-18
Publishing country	England
Document type	Journal Article
ZDB-ID	1142596-9
ISSN	1872-9800 ; 0883-2889 ; 0969-8043
ISSN (online)	1872-9800
ISSN	0883-2889 ; 0969-8043
DOI	10.1016/j.apradiso.2022.110338
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ue I Zs.279: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Efficacy of Venetoclax and Azacitidine in Acute Myeloid Leukemia Compared to Azacitidine Monotherapy: Real-World Experience.

Baba, Yuta / Hida, Noriko / Sambe, Takehiko / Abe, Maasa / Kabasawa, Nobuyuki / Sakai, Hirotaka / Yoshimura, Kiyoshi / Fukuda, Tetsuya

Anticancer research

2024 Volume 44, Issue 5, Page(s) 2003–2007

Abstract: Background/aim: The combination of venetoclax (VEN) and azacitidine (AZA) (VEN+AZA) leads to higher complete remission rates and longer overall survival (OS) in patients with untreated acute myeloid leukemia (AML) who are ineligible for intensive ... ...

Abstract	Background/aim: The combination of venetoclax (VEN) and azacitidine (AZA) (VEN+AZA) leads to higher complete remission rates and longer overall survival (OS) in patients with untreated acute myeloid leukemia (AML) who are ineligible for intensive combination chemotherapy. In practice, the doses of VEN and AZA are reduced at the attending physician's discretion to avoid adverse events; however, the impact of dose and duration reductions has not been fully clarified. We analyzed whether the efficacy was maintained with reduced VEN+AZA compared to AZA monotherapy in the real world. Patients and methods: A total of 33 patients were included; 17 (10 newly diagnosed, 7 primary refractory or relapsed) received VEN+AZA, and 16 (7 newly diagnosed, 9 primary refractory or relapsed) received AZA. We analyzed complete remission (CR) and CR with incomplete hematologic recovery (CRi) rates, OS, and the incidence of adverse events. Results: CR/CRi were achieved in 7/17 (41.2%) and 11/17 (64.7%) patients in the VEN+AZA group and 0/15 (0%) and 2/15 (6.7%) patients in the AZA group, respectively. The CR/CRi rate was higher in the VEN+AZA group than in the AZA group (p=0.001). OS was longer in the VEN+AZA group than in the AZA group (p=0.03), with a median of 506 days [95% confidence interval (CI)=234-585 days] and 208 days (95% CI=52-343 days), respectively. Conclusion: The doses of the VEN+AZA combination were reduced at the attending physician's discretion, resulting in a higher CR/CRi rate and longer OS than AZA monotherapy and is considered useful for AML in the real world.
MeSH term(s)	Humans ; Azacitidine/therapeutic use ; Azacitidine/adverse effects ; Azacitidine/administration & dosage ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/mortality ; Male ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic/administration & dosage ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Female ; Aged ; Sulfonamides/therapeutic use ; Sulfonamides/administration & dosage ; Sulfonamides/adverse effects ; Middle Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Aged, 80 and over ; Treatment Outcome ; Remission Induction ; Adult
Chemical Substances	Azacitidine (M801H13NRU) ; venetoclax (N54AIC43PW) ; Bridged Bicyclo Compounds, Heterocyclic ; Sulfonamides
Language	English
Publishing date	2024-04-27
Publishing country	Greece
Document type	Journal Article ; Comparative Study
ZDB-ID	604549-2
ISSN	1791-7530 ; 0250-7005
ISSN (online)	1791-7530
ISSN	0250-7005
DOI	10.21873/anticanres.17003
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1642: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: External validation of the Michigan PICC catheter-associated bloodstream infections score (MPC score) for predicting the risk of peripherally inserted central catheter-associated bloodstream infections: A single-center study in Japan.

Sakai, Hirotaka / Iwata, Mitsunaga / Terasawa, Teruhiko

Infection control and hospital epidemiology

2021 Volume 44, Issue 3, Page(s) 480–483

Abstract: The Michigan peripherally inserted central catheter-associated bloodstream infection score (MPC score) had been developed for hospitalized medical patients but had not been externally validated. A retrospective analysis of a clinically heterogeneous case- ...

Abstract	The Michigan peripherally inserted central catheter-associated bloodstream infection score (MPC score) had been developed for hospitalized medical patients but had not been externally validated. A retrospective analysis of a clinically heterogeneous case-mix in a university hospital cohort in Japan failed to validate its originally reported good performance.
MeSH term(s)	Humans ; Catheterization, Central Venous/adverse effects ; Retrospective Studies ; Michigan/epidemiology ; Japan/epidemiology ; Risk Factors ; Catheter-Related Infections/diagnosis ; Catheter-Related Infections/epidemiology ; Sepsis ; Catheterization, Peripheral/adverse effects ; Catheters ; Central Venous Catheters
Language	English
Publishing date	2021-12-20
Publishing country	United States
Document type	Journal Article
ZDB-ID	639378-0
ISSN	1559-6834 ; 0195-9417 ; 0899-823X
ISSN (online)	1559-6834
ISSN	0195-9417 ; 0899-823X
DOI	10.1017/ice.2021.497
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1714: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Chronic neutrophilic leukemia preceded by myelodysplastic syndromes.

Baba, Yuta / Nakamaki, Tsuyoshi / Sakai, Hirotaka / Fukuchi, Kunihiko / Kabasawa, Nobuyuki / Hattori, Norimichi / Harada, Hiroshi

International journal of hematology

2023 Volume 118, Issue 5, Page(s) 636–641

Abstract: Chronic neutrophilic leukemia (CNL) is primarily diagnosed by excluding myelodysplastic syndromes (MDS). We report the case of a patient who developed secondary CNL 3 years after hypoplastic MDS. We used droplet digital polymerase chain reaction mutation ...

Abstract	Chronic neutrophilic leukemia (CNL) is primarily diagnosed by excluding myelodysplastic syndromes (MDS). We report the case of a patient who developed secondary CNL 3 years after hypoplastic MDS. We used droplet digital polymerase chain reaction mutation detection assay to analyze genomic alterations during the progression from MDS to CNL. At the time of MDS diagnosis, U2AF1 Q157P and SETBP1 D868N were dominant and additional mutation of ASXL1 1934_insG was observed. CSF3R T618I and SETBP1 D868N were increasing at the time of CNL diagnosis. We revealed the accumulation of multiple gene mutations during CNL development from MDS. This suggests that CNL was clonally developed from the founding clone of MDS and CSF3R mutation contributes to the development of CNL in the present case. These findings provide insights into the pathology of CNL.
MeSH term(s)	Humans ; Leukemia, Neutrophilic, Chronic/complications ; Leukemia, Neutrophilic, Chronic/genetics ; Leukemia, Neutrophilic, Chronic/diagnosis ; Myelodysplastic Syndromes/complications ; Myelodysplastic Syndromes/genetics ; Mutation
Language	English
Publishing date	2023-07-13
Publishing country	Japan
Document type	Case Reports ; Journal Article
ZDB-ID	1076875-0
ISSN	1865-3774 ; 0917-1258 ; 0925-5710
ISSN (online)	1865-3774
ISSN	0917-1258 ; 0925-5710
DOI	10.1007/s12185-023-03636-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 269: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito